Glans, Hedvig ORCID: 0000-0002-7401-2245, Dotevall, Leif, Van der Auwera, Gert, Bart, Aldert, Blum, Johannes, Buffet, Pierre, Guery, Romain ORCID: 0000-0002-9129-7799, Gangneux, Jean-Pierre ORCID: 0000-0002-4974-5607, van Henten, Saskia ORCID: 0000-0001-6627-0474, Harms, Gundel, Varani, Stefania, Robert-Gangneux, Florence, Rongisch, Robert, Andersson, Bjorn ORCID: 0000-0002-4624-0259 and Bradley, Maria (2022). Treatment outcome of imported cutaneous leishmaniasis among travelers and migrants infected with Leishmania major and Leishmania tropica: a retrospective study in European centers 2013 to 2019. Int. J. Infect. Dis., 122. S. 375 - 382. OXFORD: ELSEVIER SCI LTD. ISSN 1878-3511

Full text not available from this repository.

Abstract

Objectives: Cutaneous leishmaniasis (CL) in Asia, Northern, and Sub-Saharan Africa is mainly caused by Leishmania major and Leishmania tropica. We describe and evaluate the treatment outcome of CL among travelers and migrants in Europe.Methods: We conducted a retrospective study of parasitological confirmed CL cases caused by L. major and L. tropica during 2013-2019 in Europe. Data were collected from medical records and databases within the LeishMan network.Results: Of 206 included cases of CL, 75 were identified as L. major and 131 as L. tropica. Of patients with L. tropica infection, 80% were migrants, whereas 53% of patients with L. major infection had been visiting friends and relatives. Among patients with L. tropica, 48% were younger than 15 years. Pentavalent antimony cured 73% ( L. major ) and 78% ( L. tropica) of patients. The cure rate for intralesional administration was 86% and 67% for systemic, on L. tropica. Liposomal amphotericin B had a cure rate of 44-63%. Conclusion: L. major infections were mostly found in individuals visiting friends and relatives, whereas L. tropica were mainly identified in migrants. No patients with L. major relapsed. Pentavalent antimony, liposomal amphotericin B, and cryotherapy had cure rates in accordance with previous studies.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Glans, HedvigUNSPECIFIEDorcid.org/0000-0002-7401-2245UNSPECIFIED
Dotevall, LeifUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Van der Auwera, GertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bart, AldertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blum, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buffet, PierreUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guery, RomainUNSPECIFIEDorcid.org/0000-0002-9129-7799UNSPECIFIED
Gangneux, Jean-PierreUNSPECIFIEDorcid.org/0000-0002-4974-5607UNSPECIFIED
van Henten, SaskiaUNSPECIFIEDorcid.org/0000-0001-6627-0474UNSPECIFIED
Harms, GundelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Varani, StefaniaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robert-Gangneux, FlorenceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rongisch, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Andersson, BjornUNSPECIFIEDorcid.org/0000-0002-4624-0259UNSPECIFIED
Bradley, MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-695804
DOI: 10.1016/j.ijid.2022.06.025
Journal or Publication Title: Int. J. Infect. Dis.
Volume: 122
Page Range: S. 375 - 382
Date: 2022
Publisher: ELSEVIER SCI LTD
Place of Publication: OXFORD
ISSN: 1878-3511
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
LIPOSOMAL AMPHOTERICIN-B; MEGLUMINE ANTIMONIATE; MUCOSAL LEISHMANIASIS; CLINICAL-TRIAL; EFFICACY; CRYOTHERAPY; FLUCONAZOLE; PAROMOMYCIN; FORMULATIONMultiple languages
Infectious DiseasesMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69580

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item